We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 443

S. 8 case not struck, despite prohibition order having issued in underlying s. 6 proceeding

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • December 4 2014

In this case, the Prothonotary refused to strike a Statement of Claim brought pursuant to s. 8 of the NOC Regulations, and this decision was upheld

Pfizer seeks amendment of Supreme Court’s judgment on VIAGRA patent or alternatively a re-hearing on remedy

  • SIM. IP Practice
  • -
  • Canada
  • -
  • November 19 2012

In a rare move, Pfizer has filed a motion seeking to amend the Supreme Court of Canada’s judgment on its VIAGRA patent, or alternatively for a re-hearing on the issue of remedy

Teva v Pfizer, or the “Viagra saga”: if there is no quid proper disclosure there can be no quo exclusive monopoly rights

  • Fasken Martineau DuMoulin LLP
  • -
  • Canada
  • -
  • November 19 2012

Sildenafil is the active ingredient in Viagra, the blockbuster potency-enhancing drug marketed by Pfizer

Court of Appeal again interprets utility requirement in Celebrex FCA

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • November 1 2014

The Federal Court of Appeal has again discussed the so-called “promise doctrine” in its October 30, 2014 decision of Apotex Inc. v. Pfizer Canada Inc

Sanofi-Aventis, et al. V. Apotex Inc., et al.

  • Bereskin & Parr LLP
  • -
  • Canada
  • -
  • November 10 2014

On October 30, the Supreme Court of Canada granted leave to appeal from the Federal Court of Appeal (FCA) decision in Apotex Inc. v. Sanofi-Aventis

Re-litigation by a patentee with a different party has the federal court been consistent in its approach?

  • SIM. IP Practice
  • -
  • Canada
  • -
  • November 26 2014

Over the past few years the pharmaceutical marketplace has seen an increase in patent "re-litigation" (where a patentee is involved in a second case

The Supreme Court of Canada grants leave to appeal in the Plavix case

  • Bereskin & Parr LLP
  • -
  • Canada
  • -
  • January 30 2014

The Supreme Court of Canada announced today that it has granted leave to appeal to Apotex Inc. from the Federal Court of Appeal (FCA) in the patent

Supreme Court grants Apotex leave to consider PLAVIX patent for the second time

  • Smart & Biggar/Fetherstonhaugh
  • -
  • Canada
  • -
  • January 31 2014

On January 30, 2014, the Supreme Court of Canada granted Apotex Inc. leave to appeal a decision of the Federal Court of Appeal which overturned a

Listing patents against combination drugs in Canada ? Changes coming

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • December 1 2014

On Nov. 26, 2014, Industry Canada announced an important proposed change to the eligibility requirements for listing a patent against a drug in

Methods of medical treatment and dosage claims

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • June 28 2011

In Canada, claims to methods of medical treatment are considered to fall outside the definition of invention according to section 2 of the Patent Act and a decision of the Supreme Court of Canada